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Abstract
Interstitial lung disease in children represents a group of rare chronic respiratory disorders. There
is growing evidence that mutations in the surfactant protein C gene play a role in the pathogenesis
of certain forms of pediatric interstitial lung disease. Recently, mutations in the ABCA3 transporter
were found as an underlying cause of fatal respiratory failure in neonates without surfactant protein
B deficiency. Especially in familiar cases or in children of consanguineous parents, genetic diagnosis
provides an useful tool to identify the underlying etiology of interstitial lung disease. The aim of this
review is to summarize and to describe in detail the clinical features of hereditary interstitial lung
disease in children. The knowledge of gene variants and associated phenotypes is crucial to identify
relevant patients in clinical practice.
Review
Interstitial lung disease in children
Interstitial lung disease (ILD) in children represents a het-
erogeneous group of rare respiratory disorders character-
ised by restrictive lung disease and diffuse pulmonary
infiltrates. Affected children usually present with dry
cough, dyspnoea and tachypnoea. Physical findings show
elevated resting respiratory rate and rales (or crackles)
mostly more pronounced in the basal segments of the
lungs. In children suffering from severe ILD, chronic
hypoxemia, cyanosis, finger clubbing and growth failure
occur [1,2]. High-resolution computed tomography pro-
vides detailed diagnostic information about the extent
and distribution of the lung pathology and has become
the most relevant imaging technique for ILD in children
[3]. However, the diagnostic gold standard is still the lung
biopsy where the characteristic histological findings of
inflammation in the pulmonary interstitium with wall
thickening by inflammatory cells and/or fibrosis can be
found. At present, no pathognomonic laboratory criteria
for the diagnosis of ILD in children are available [4]. ILD
is associated with pulmonary inflammation which can
resolve completely, partially or can progress to fibrosis.
The factors determining the progression of ILD are not
well understood but an interaction between genetic back-
ground and environmental modifiers is suggested [1,5-7].
In children, ILD is less frequent and comprises a broader
spectrum of disorders with a more variable clinical course
compared to adults. In addition, there are special disease
entities which predominantly occur in children, like the
recently described pulmonary interstitial glycogenosis [8],
the neuro-endocrine cell hyperplasia of infancy [9] and
the genetic disorders of surfactant metabolism [10]. Most
Published: 08 April 2005
Respiratory Research 2005, 6:32 doi:10.1186/1465-9921-6-32
Received: 09 January 2005
Accepted: 08 April 2005
This article is available from: http://respiratory-research.com/content/6/1/32
© 2005 Hartl and Griese; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
Page 2 of 16
(page number not for citation purposes)
of the information on ILD in childhood is based on stud-
ies performed in adults. In the recent years, however, there
is increasing evidence that ILD in children differs substan-
tially from adult ILD [2]. PediatricILD occur in the context
of lung development and are most frequent diagnosed in
the first year of life when alveolar development is taking
place [11,12]. The combination of epidemiological rarity,
clinical heterogenity and genetic background makes the
classification of ILD in children difficult. Thus, studies up
to now included only limited numbersof patients, except
of one recent study encompassing 185 children [13], and
no randomised controlled trials have been performed to
evaluate treatment strategies.
Mutations in surfactant protein B (SP-B) cause fatal respi-
ratory distress in neonates [14]. Recently, mutations in the
SP-C gene and in the ATP-binding cassette protein A3
(ABCA3) gene were found to be associated with pediatric
ILD [15-17]. SP-C gene variants presented as a variable
clinical phenotype. While children with SP-C mutations
showed mostly non-specific interstitial pneumonitis
(NSIP) except of two cases with combined pulmonary
alveolar proteinosis (PAP), adults with SP-C mutations
suffered from usual interstitial pneumonitis (UIP) or
desquamative interstitial pneumonitis (DIP) or remained
asymptomatic. ABCA3 mutations were associated with
fatal respiratory failure in neonates without SP-B or SP-C
deficiency and with non-fatal ILD in one older child.
These infants showed a diagnosis of PAP, DIP or chronic
pneumonitis of infancy (CPI) [18].
The aim of this review is to summarize and describe in
detail the reported clinical courses of hereditary ILD in
children. At first, the role of surfactant protein B in ILD is
described. It is delineated how SP-B deficiency results in
lung disease in mouse models and in humans. Reported
single cases with partial SP-B deficiency are discussed in
detail. Similarly, the role of surfactant protein C in ILD is
reviewed and a model of surfactant protein C associated
lung disease is described. Finally, the roles of ABCA3 and
of further genes involved in surfactant protein expression,
lung morphogenesis and lamellar body synthesis are dis-
cussed. The diversity of gene variants and associated phe-
notypes illustratesthe overlap between genetic defect,
environmental influence and the resulting respiratory dis-
ease. Knowledge on the clinical features of hereditary ILD
is crucial to identify relevant patients for genetic analysis
in clinical practice.
Surfactant
The alveolus of the human lung tends to collapse at the
end of the expiration due to high surface tension. A phos-
pholipid film, named surfactant, holds alveolar stability
at the air-liquid interface by reducing surface tension. Sur-
factant is a mixture of lipids and proteins, which contains
70 – 80% phospholipids, 10% protein and about 10% of
neutral lipids. When surfactant is lacking at birth, the alve-
oli collapse, the alveolo-capillary membranes become
leaky and intra-alveolar hyaline membranes occur,
termed as respiratory distress syndrome (RDS). Surfactant
is synthesized and secreted by type II epithelialcells. Sur-
factant proteins can be divided into the hydrophobic pro-
teins SP-B and SP-C and the hydrophilic proteins SP-A
and SP-D. While SP-A and SP-D play essential roles in the
pulmonary immune defense, SP-B and SP-C lower the sur-
face-tension and facilitate formation and stabilization of
the surfactant film [19,20].
Surfactant protein B
Structure and biosynthesis
Human SP-B is encoded on the short arm of chromosome
2 and spans about 10 kilobases. The SP-B gene contains
11 exons, with the 11th exon being untranslated, and is
transcribed into a ~2000 base pair mRNA [21-23]. Corti-
costeriods were found to enhance the SP-B transcription
[24], while Transforming Growth Factor-β  (TGF-β ), NO
and insulin inhibited the transcriptional process [25,26].
The SP-B gene is expressed in type II cells and in non-cili-
ated bronchiolar epithelial cells, but only type II cells are
able to fully process the inital translation product, pro-SP-
B, to functionally active, mature SP-B. In a first step, the
SP-B mRNA is translated into a preproprotein of 381-
amino acids [23,27-29]. After removal of the first 23
amino acids, the remaining proprotein (proSP-B) is prote-
olytically processed at the amino-, and carboxy-terminal
ends to the mature SP-B of 79 amino acid. The cysteine
protease, cathepsin H and the aspartyl protease, Napsin A,
highly expressed in type II epithelial cells, have been
implicated recently in processing of the SP-B and SP-C
propeptides [30-32].
Surfactant protein B deleted mice
After birth, SP-B deleted mice showed normal respiratory
efforts but failed to inflate the lungs, were cyanotic and
died rapidly due to severe respiratory failure [33]. Histo-
logically, their lungs showed a normal morphogenesis
without signs of inflammation. Pulmonary function test-
ing revealed decreased lung volumesand an absence of
residual volume at end-expiration, similar to neonates
with RDS. Furthermore, no proSP-B or SP-B protein were
detected and no tubular myelin and lamellar bodies were
found in lungs of these mice. Interestingly, an aberrant
form of proSP-C of 12-kd and abundance of SP-A and SP-
C mRNA were detected in these lungs, but fully processed
SP-C protein was found to be decreased. Type II alveolar
cells of these mice contained notypical lamellar bodies
and showed enlarged multivesicularbodies with small
lipid vesicles, which suggests a role for SP-B in the packing
of surfactantphospholipids into lamellar bodies [34,35].
These findings in SP-B deficient mice indicate thatSP-B isRespiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
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critical for reduction of surface tension in the alveolus, for
the proteolytic processing of proSP-C, for the arrangemen-
tof surfactant phospholipids in lamellar bodies and for
lung functionduring the early neonatal period.
Surfactant protein B deficiency in human lung disease
SP-B deficiency was the first reported genetic cause of
lethal RDS in infants [36]. A full-term newborn died in the
neonatal period from unclear lung disease. An open lung
biopsy revealed the histopathological features of congen-
ital PAP, a pathology which had been observed previously
in several full-term neonates with severe respiratory fail-
ure, mostly with a family history of neonatal respiratory
disease [37], suggesting an autosomal-recessive inherit-
ance. In lung tissue of the patient, mature SP-B was unde-
tectable whereas SP-A and proSP-C were regularly found.
Genetic analysis revealed that the affected infant was
homozygous for a frameshift mutation in codon 121
(termed 121ins2 mutation) in the SP-B gene [38,39]. The
121ins2 loss-of-function mutation is suggested to account
for up to two-thirds of the mutant alleles identified in the
SP-B locus. At least 27 loss of function mutations were
found in the SP-B gene that resulted in neonatal RDS [40-
48]. Since most of these mutations were unique to the
index families the sensitivity of genetic counseling is lim-
ited. The incidence of hereditary SP-B deficiency is not
known, but an allele frequency of 1 per 1000–3000 indi-
viduals for the 121ins2 mutation is suggested [45,47-49].
The phenotype of infants with hereditary SP-B deficiency
is described as typically full-term neonates with severe
RDS who are refractory to standard therapies, includ-
ingventilation and surfactant replacement. Chest X-rays
usually show diffuse ground glass pattern in both lung
fields consistent with a diagnosis of hyaline membrane
disease. PAP was found as the predominant pulmonary
phenotype of the first identified infants with SP-B defi-
ciency, which was not the case for all infants with this
genetic disorder. Recently, a study of neonates and chil-
dren with severe unexplained respiratory distress and PAP
revealed that the majority of cases with PAP was not
linked to SP-B gene mutations [48].
Histologically, SP-B deficiency in humans has been asso-
ciated with PAS-positive eosinophilic material in the alve-
oli, epithelial cell desquamation, enlarged alveolar
macrophages with lamellar inclusions and abundant
accumulation of SP-A [50,50]. Since SP-B was found to be
essential for the proteolytic processing of proSP-C
[34,51], newborns with hereditarySP-B deficiency show
aberrantly processed SP-C in theintra-alveolar lumen
[50,52-54]. Furthermore, an abnormal surfactant activity
and altered levels of phosphatidylglycerol were observed
in SP-B deficient patients [42,52,55].
Although SP-B deficient neonates usually present with res-
piratory failure in the first 24 to 48 hours of life, the clin-
ical diagnosis can sometimes be delayed since affected
infants may show initially mild symptoms and do not
require ventilation or further medical support for some
time. The lung disease however is rapidly progressive and
fatal respiratory failure finally sets in within 3–6 months,
even with maximal medical efforts [56] and lung trans-
plantation is suggested as the only effective treatment
[57]. Despite a possible, transient beneficial effect, exoge-
nous surfactant in SP-B deficient infants was found to be
largely ineffective [58,59]. This lack of response of sur-
factant replacement in SP-B deficient infants may be due
to an additional function of SP-B precursors, to the accu-
mulation of aberrant SP-C which may inhibit surface film
formation or due to an impairment of SP-B recycling [10].
Partial surfactant protein B deficiency
There is increasing evidence that some SP-B mutations
may result in milder pulmonary phenotypes. In mice with
heterozygous disrupted SP-B production, the reduced SP-
B synthesis led to chronic lung damage when exposed to
hyperoxia [60]. Exogenous SP-B corrected this oxygen-
induced pulmonary dysfunction [61].
So far, four patients with partial SP-B deficiency are
described in the literature. Characteristics of these patients
are described in table 1 (Additional file 1).
Case 1 (mutation: G135S)
A male neonate presented during the first hours of life
with respiratory distress and required mechanical ventila-
tion. The patient developed persistent pulmonary hyper-
tension and was treated with continous oxygen therapy.
Biochemical analyses of his tracheal aspirate fluid
revealed a complete absence of SP-B and an aberrant form
of SP-C at 12 kd, suggesting the diagnosis of hereditary SP-
B deficiency. A genetic analysis demonstrated a point
mutation in exon 5 on one SP-B allele and the mother was
found to be the carrier. Histological sections of the lung
revealed PAP. The authors suggested that this patient had
a transient SP-B deficiency caused by a SP-B gene variant.
The patient developed chronic lung disease and was alive
at 3 years of age requiring oxygen supplementation [62]
Case 2 (mutation: 121ins2/R236C)
The most severe course of partial SP-B deficiency was a
full-term infant who developed tachypnea shortly after
birth. A chest radiogram showed bilateral pneumonitis.
Because of poor oxygenation, the infant received extracor-
poreal membrane oxygenation (ECMO) and remained
oxygen dependent for 9 months. The patient showed a
beneficial response to corticosteroids and withdrawals of
steroid therapy worsened his status dramatically. At 8
months of age, no SP-B was detected in BAL and a geneticRespiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
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analysis revealed a heterozygous state for the 121ins2
mutation. The other allele carried a point mutation
(R236C). The mother was identified as the carrier for the
121ins2 and the father of the R236C allele. Since his pul-
monary situation deteriorated rapidly, he was accepted for
lung transplantation but died at the age of 9 months of
unexplained sudden respiratory failure and cardiac arrest.
Cases 3 & 4 (mutation: c.479G>T)
Two unrelated children homozygous for a mutation in
exon 5 (479G→ T) of the SP-B gene have been reported.
The genetic defect resulted in reduced SP-B levels and an
unclear lung disease. The first patient was born at 40
weeks of gestation and showed RDS at 8 hours of age. Fur-
thermore, he developed a spontaneouspneumothorax at
18 hours of age. He required continous oxygen supple-
mentation and dexamethasone seemed to have no influ-
ence onhis respiratory symptoms. At 5 weeks of life, he
underwent an open lungbiopsy. Hisrespiratory function
declined progressively and he underwentbilateral lung
transplantation at 4 months of age.
The second patient was a full-term female who developed
RDS shortly after birth. The patient did not require
mechanical ventilation but had a persistentoxygen
requirement. At 2 months ofage, an open lung biopsy was
performed which showed interstitialfibrosis and PAP.
Diuresis, steroid therapy and cyclophosphamide therapy
had no beneficial effect on her pulmonary symptoms and
she developed pulmonary hypertension andright ven-
tricular hypertrophy. At 6 months ofage she was dis-
charged with home oxygen therapy and has been stable
for several years with persistent oxygen requirement [63].
The histological phenotype of partial SP-B deficiency
included accumulationof extracellular proteins, atypical
macrophages, epithelial-celldysplasia and pulmonary
fibrosis. However it remained unclear whether these path-
ologicalfindings were caused by impaired surface tension,
by accumulationof abnormal SP-B or by other factors that
may causethese forms ofILD. The patients with partial SP-
B deficiency were bearing uncommon mutations leading
either to the production of small amounts of SP-B or to
proSP-B which was not further processed to mature SP-B
[62-64]. A critical SP-B level required for physiological
lung function has been suggested, which is supported by
experiments in mice which developed lung disease when
SP-B levels were genetically downregulated below 20–
25% of physiological values [65]. Since SP-B levels in the
reported cases were not evaluated during the course of dis-
ease, the association between levels of SP-B and respira-
tory status could not be assessed.
Surfactant protein B polymorphisms
Polymorphisms in the SP-B gene or an interaction
between SP-A and SP-B gene products may act as genetic
determinants for the susceptibility to RDS [66-68]. The
SP-B gene contains two polymorphisms, the Ile131Thr
locus and a polymorphic site in intron 4. A length varia-
tion in intron 4 has been proposed to associate withRDS
independently [69] and in combination with an SP-A
allele [70]. The Ile131Thr polymorphism affects a putative
N-linked glycosylation site of proSP-B which may play a
role in the genetic susceptibility to RDS in premature
neonates. Furthermore, the SP-B Ile131Thr polymor-
phism may be linked to an unknown genetic element that
increases the risk of RDS in cooperation with SP-A allelic
variants [66,68]. A large study of premature neonates
found no association of the two SP-B polymorphisms
with RDS, but showed that the association between SP-A
alleles and RDS was dependenton the SP-B Ile131Thr gen-
otype [71]. A consanguineous pedigree with 14 infants
dying of neonatal RDS had biochemically a SP-B defi-
ciency. Molecular analyses showed nine SP-B polymor-
phisms but none of them could explain the observed SP-
B deficiency. Interestingly, in lung tissue of these patients
aberrant SP-B mRNA was found [72]. A further study of
SP-A and SP-B genetic variants in singletons and twins
found no direct genetic influence on the risk of RDS [73].
Surfactant protein C
Structure and biosynthesis
SP-C is the only surfactant-associated protein that isexclu-
sively expressed in typeII pneumocytes [74]. The SP-C
gene is encoded on the short arm of human chromosome
8 and contains 6 exons. The mature SP-C is encoded in
exon 2 and the sixth exon is being untranslated. SP-C is
synthesizedby proteolytical processing of the larger pre-
cursor protein proSP-C [54]. The SP-C gene is transcribed
into an 900 bp mRNA and is translated into the 197
amino acid proprotein (proSP-C). Alternative splicing
atexon 5 results in a shorter transcript of 191-amino acid
proprotein but the physiological role of the splice variant
is not known [75]. The SP-C precursor protein isrouted
together with the SP-B precursor protein to multivesicu-
larbodies, where both proteins are processed and pack-
aged into lamellarbodies for secretion into the alveolus
[51]. ProSP-C is extensively processed posttranslationally,
similar to proSP-B. Recently, the proteases cathepsin H
[30] and Napsin A [76] were found to be involved in the
first N-terminal processing step of proSP-C. Furthermore,
the SP-C peptide is modified posttranslationally by palmi-
toylation at cysteine residues at positions 5 and 6 [54].
The mature SP-C peptide of 35-amino-acids is stored in
the lamellar body from where it is secreted into the alveo-
lar space.Respiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
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Surfactant protein C deleted mice
While SP-B was shown to play a critical role in neonatal
lung function, SP-C seems to be involved in a different
way.
Swiss black outbred mice [35]
The initial strain of SP-C knock-out mice (Swiss black out-
bred) was viable and had normal lung function. Lung tis-
sues showed subtle pulmonary abnormalities with regular
lamellar bodies, reduced viscoelasticity and decreased sta-
bility of surfactant bubbles. SP-C mRNA was not detected
in the lungs of these mice and no mature SP-C protein was
found. BAL fluid levels of SP-A, SP-B and SP-D were simi-
lar compared to wild-type mice and pulmonary structures
were normal with no indication of inflammation. The
number of type II pneumocytes was similar compared to
wild type and well-organized lamellar bodies and tubular
myelin were detected in the SP-C -/- strains. However,
lung mechanics showed a lower hysteresivity (mechanical
coupling between tissue resistance and elastance) in SP-C
-/- mice at the end-expiratory pressure (low PEEP), sug-
gesting that SP-C stabilizes the phospholipid film at
reduced lung volumes. The surface activity of large aggre-
gate surfactant from SP-C -/- mice was similar to SP-C
wild-type mice, but the stability of small bubbles was
decreased in surfactant of SP-C -/- mice.
This SP-C -/- genetic model showed marked differences
compared to the SP-B knock-out model and suggests, (1)
that SP-C is not essential for the synthesis or secretion of
pulmonary surfactant, (2) that SP-C plays an important
role in the stabilization of phospholipid packing at small
bubble radius and (3) that SP-C is involved in the recruit-
ment of phospholipids from the subphase to the surface
film. Thus, SP-C may play a more important role in the
stabilizationof surfactant rather than in its synthesis [35].
129/Sv strain mice [77]
Interestingly, when these SP-C-deficient mice were gener-
ated in a different genetic background (129/Sv strain) they
developed a more severe lung disease. While lung struc-
ture was normal at birth, a progressive air space enlarge-
ment, emphysema, macrophage infiltration, abnormal
tissue lipid accumulation and pulmonary fibrosis was
observed within 2 months after birth. At the age of 6
months, parenchymal infiltrates and type II cell hyperpla-
sia were found. Furthermore, these lungs showed activa-
tion of metalloproteases, fragmentationof elastin fibers
and infiltration of myofibroblasts in thealveolar septa,
similar to findings ofILD in humans. The pulmonary
alterations increased progressively with age and at one
year of age, the mice developed pneumonitis and emphy-
sema. Analysis of lung mechanics revealed that lung vol-
umes were significantly increased in SP-C -/- mice as
compared to wild type mice, consistent with the histolog-
ically observed emphysema. Biochemical analyses
showed normal levels of SP-B while levels of SP-A and SP-
D were increased.
This knock-out mouse model shows that lack of SP-C
causes chronic lung disease depending on the genetic
background suggesting that SP-C associated lung disease
may be triggered by environmental factors and/or modi-
fier genes [77].
Surfactant protein C deficiency in human lung disease
There is increasing evidence linking SP-C deficiency to
various types of ILD in humans [10,78,79]. While SP-B
deficiency generally results in fatal neonatal lung disease,
abnormal expression of SP-C has been shown to present
as a much more variable phenotype [78,80-89]. Amin et
al. found an association between abnormalities in SP-C
expression and familial ILD. Three family members with
chronic ILD had no detectable levels of SP-C and
decreased levels of SP-A and SP-B in their BAL fluid.
Immunostaining showed a decreased expression of
proSP-C in the alveolar epithelial cells, but no mutations
in the exons of SP-B or SP-C were found. Thus the under-
lying mechanism responsible for the lack of SP-C in these
patients remained unknown [90].
Table 2 (Additional file 1) summarizes reported cases of
ILD associated with SP-C gene variants. Since the clinical
courses showed a large variance, each report is described
separately.
Case report on SP-C deficiency with mutation c.460+1 G>A / ∆ exon 
4 [83]
The first report on SP-C deficiency was a female infant
whose family history showed a three-generation history of
ILD inherited in an autosomal-dominant way. The
mother was given a diagnosis of DIP at one yearof age and
she had been treated with glucocorticoids until the age of
15 years. Her father had diedfrom an unclear chronic lung
disease without a diagnosis. The women delivered a full-
term baby with no respiratory symptoms at birth. This
infant developed tachypnea and cyanosis at six weeks of
age and chest radiographs showed interstitial involve-
ment. An open-lung biopsy was performed andshowed
NSIP. Mature SP-C could not be detected. Sequencing of
the SP-C gene revealed a single base donor splice site
mutation with substitution of the first base of intron 4
(c.460+ 1G > A) leading to the skipping of exon 4 and a
shortened SP-C proprotein. This mutation was identified
on only one allele of the SP-C gene suggesting an auto-
somal-dominant way of inheritance. The patient's mother
also had reduced expression of proSP-C and the same SP-
C mutation was found. The girlwas treated with oxygen
and glucocorticosteroids andher respiratory symptomsRespiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
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improved. After delivery the lung disease of the mother
worsened and she died from respiratoryfailure.
Furthermore, Nogee et al. analyzed the SP-C gene
sequence in 34 infants with chronic lungdisease of
unknown etiologyand found heterozygous mutations in
11 of 34 patients. Similar to the initially described patient,
these mutations led to skippingof exon 4, expression of an
aberrant proSP-C and decreased expression of normal SP-
C. In 10 infants, with 6 showing a family history of ILD,
missense SP-C mutations resulting in amino-acid substi-
tutions (P30L, I73T, G100V, Y104H, P115L, I126R,
T187N and L188R)and a frameshift mutation (140delA)
associated with expressionof a stable transcript, were iden-
tified. Recently, neonates with severe RDS carrying muta-
tions in the SP-C gene were described [91]. Exon 4 deleted
SP-C constructs concentrated in perinuclear aggregates
which have been shown to be toxic for the developing
mouse lung [92]. Furthermore, co-transfection with wild-
type and exon 4 deleted SP-C constructs resulted in a pat-
tern similar to the mutant SP-C construct, suggesting a
dominant-negative mechanism in heterozygous SP-C
mutations [93].
Familial SP-C deficiency with mutation c.588 T>A / L188Q [81]
Thomas reported a large kindred of 16 individuals with
adults suffering from UIP and children from cellular
NSIP. Genetic analyses found a heterozygous T>A trans-
version at exon 5 + 128 which led to a substitution of a
glutamine for leucine at the highly conserved amino acid
position 188 of the C-terminus of proSP-C, a region
which is essential for intracellular protein trafficking.
Immunostaining showed an aberrant subcellular localiza-
tion of SP-C precursor protein, dense fibrosis and dis-
torted cellular architecture with alveolar type II cell atypia
and abnormal lamellar bodies. These findings were simi-
lar to those which have been described in type II cellular
death or apoptosis [94,95]. When mouse type II cells
(MLE cells) were transfected with this SP-C mutation, a
similar morphology was found with atypical inclusions
resembling lamellarbodies. Furthermore, expression of
the mutant protein resulted ina threefold increase of cyto-
toxicity compared to the wild-type.
Since the identical SP-C mutation caused different patho-
logic phenotypes (UIP, NSIP) in affected relatives, it has
been suggested that SP-C dependent lung diseases may
represent pleiotropic manifestations of the same underly-
ing pathogenesis and the mutation may result indifferent
histological patterns dependent on the age of manifesta-
tion. It is also possible that in this family, cellular NSIP in
the affected children occurred as a precursor lesion to UIP
in adulthood, but the discrimination of theseentities is
discussed controversial [96-98]. Interestingly, two mem-
bers of the index family with heterozygous SP-C muta-
tions were unaffected. Therefore, the mutation in this
kindred showed incomplete penetrance and secondary
genetic and/or environmental modifiers may affectthe
disease progress.
Case report on SP-C deficiency with mutation in exon 3 [86]
A full-term female of two parents without a history of pul-
monary disease thrived normally until the age of 3
months. Then, she developed respiratory symptoms with
diffuse interstitial infiltrates. The airway surfactant con-
tained decreased levels of mature SP-B and SP-C. An open
lung biopsy at 6 months of age revealed an interstitial
pneumonitis without an underlying cause. Minimum pul-
monary surface tension was increased. SP-C mRNA was
present in normal size and amount, but proSP-C was
aggregated within type II cells in a compartment separate
from SP-B. The cells contained both normal and disorgan-
ized lamellar bodies. A genetic analysis was performed
and revealed a 9-bp deletion in exon 3 of the SP-C gene.
This in-frame mutation spanning codons 91–93 was
present on one allele only. Since the parents did not carry
this deletion a de novo mutation was suggested. The
patient's lung function and physical capacity declined dra-
matically and a bilateral lung transplantation was per-
formed with 14-months of age. The patient's course
ameliorated and at 30 months she was breathing ambient
air and was gaining weight.
Case reports on SP-C deficiency with mutation c.243 T>C / I73T and 
c.525 G>A / R176Q [80]
In a group of 34 sporadic and familial cases with RDS, in
which SP-B mutations had been excluded, two distinct
heterozygous SP-C missense mutations were found. The
first case was a full-term boy with a normal neonatal
course who developed slight respiratory symptoms at the
age of 1 month. At age of 9 months, he failed to thrive and
his dyspnoea worsened countinously, so he required oxy-
gen supplementation. A subsequent lung biopsy showed
PAP combined with ILD. PAP has not yet been described
before in patients with SP-C gene variants. Treatment with
repetitive whole-lung lavage and systemic corticosteroids
and azathioprine resulted in an amelioration of his pul-
monary symptoms. Since biochemical BAL fluid analysis
showed normal levels of SP-B and SP-C but aberrant
forms of proSP-C, a genetic analysis of the SP-C gene was
performed. A missense mutation (c.243 T > C) in exon 3
of the SP-C gene was identified, which resulted in the sub-
stitution of threonine for a highly conserved isoleucine
(I73T). This mutation was not detected in the parents.
Similar to the other SP-C mutations, this mutation was
heterozygous, consistent with dominant inheritance [88].
In contrast to the initial patient of Nogee [83], where no
SP-C could be detected, in this patient mature SP-C pro-
tein was present together with an abnormally processed
proSP-C suggesting that the mutation altered theRespiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
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processing of proSP-C but allowed the production of
mature SP-C.
Brasch et al [88] characterizedthe intracellular trafficking
of the I73T mutation in vitro using a EGFP/proSP-CI73T
fusion protein. When transfected into A549 cells, the
mutant proSP-C was routed to early endosomes which is
in contrast to previously described SP-C mutations which
led to the formation of intracellular proSP-C aggregates
[80,93].
Recently, a further de novo I73T mutation was found in a
full-term infant with PAP and ILD showing a more severe
clinical course as compared to the previous case with this
mutation. After recurrent bacterial infections, the patient
died from respiratory failure at the age of 19 months [99].
The second SP-C mutation of Tredano et al. was found in
two patients with PAP from the endogamous white settler
population of Réunion Island in which unexplained res-
piratory distress (URD) has an unexpectedly high preva-
lence. These two patients had a similar age at the onset of
disease of 9 months. However, one infant died from lung
disease at age of 18 months, while the other one showed
a mild ILD, which was treated by repetitive therapeutic
BALs. Both patients showed an abnormal proSP-C, and
genetic analysis of the SP-C gene revealed a 2125G-A tran-
sition in exon 5, leading to an arginine 167 to glutamine
change (R167Q) in the C-terminus of the precursor pro-
tein, which is crucial for proper folding and trafficking of
proSP-C [93].
Case report on SP-C deficiency with mutation g.1509 G>A / E66K 
[82]
A full-term male showed no post-natal respiratory prob-
lems until day 13 when he was admitted to a local hospi-
tal with tachypnea, cyanosis and hypoxemia. Chest X-ray
showed diffuse bilateral pulmonary infiltrates and he
required mild ventilatory support. A lung biopsy showed
marked thickening of alveolar septa, mild interstitial
chronic inflammation and hyperplasia of type II pneumo-
cytes. The histological diagnosis of PAP and NSIP was
esthablished. Immunostaining yielded detectable levels of
SP-A, SP-B, SP-C and SP-D in BAL fluid. A DNA sequence
analysis found a heterozygous mutation in exon 2 of the
SP-C gene (1509 G>A) leading to substitution of a lysine
for glutamic acid at codon 66 (E66K). Histologically,
proSP-C expression was detected in small endosome-like
vesicles. Further in vitro trafficking studies were performed
using the EGFP/hSP-CE66K fusion protein and showed,
that the proSP-CE66K protein accumulated in early endo-
somes in contrast to ∆ exon4 and L188Q mutant con-
structs which formed intracellular aggregates.
Surfactant protein C polymorphisms
Two single nucleotide polymorphisms (SNPs) in the SP-C
coding sequence resulting in 4 allelic variants have been
described. One is localized in codon 138 that encodes
threonine or asparagines and the other one in codon 186
that codes for serine or asparagine. The allelic frequencies
or the effect of these SNPs on proSP-C processing or func-
tion are not known. Several other SNPs in non-coding
regions of the SP-C gene have been reported, but also their
functional relevance remained unclear [100-102]. Lahti et
al. analyzed the association between exonic SP-C gene
polymorphisms and their susceptibility to RDS [103]. The
study showed that SP-C polymorphisms were associated
with RDS and with premature birth but the strength of
association varied depending on to the gender of the
infants. Recently, Lawson et al found 10 SNPs in the SP-C
gene sequence of 13 of 135 analyzed adults with sporadic
UIP and NSIP but not in controls. Thus, the majority of
sporadic cases of ILD in adulthood may not be associated
with SP-Cgene variants [104].
Immunomodulatory functions of surfactant protein C
While the collectins SP-A and SP-D are well known to par-
ticipate in innate immune response, a possible role of SP-
C in pulmonary immunity has been elucidated only
recently. Inhalationof bacterial lipopolysaccharide (LPS)
induces acute airway inflammation [105] and long-term
exposure to LPS increases the risk of developing chronic
lung disease [106]. It has been shown, that the hydropho-
bic regions of SP-C bind Lipid A, a portion of LPS, in a spe-
cific and competitive way. Furthermore, SP-C was found
to interact with CD14, the cellular LPS pattern recognition
receptor which plays a central role in bacterial-induced
inflammation. The SP-C/CD14 interaction blocked the
binding of LPS to CD14 and inhibited the effect of LPS on
macrophages (Figure 1). This resulted in a decrease of pro-
inflammatory cytokine (TNF-α ) and NO release by alveo-
lar and peritoneal macrophages in response to LPS [107].
However, an in vitro study showed that SP-C didnot influ-
ence the direct binding of LPS to CD14, suggesting that
other receptors on macrophages, e.g. toll-like receptor 4 or
the complement receptor CD11/CD18 may be more
essential in this mechanism [108].
These findings indicate thatSP-C plays a role in innatelung
defense by preventing LPS-induced pulmonary inflamma-
tion. SP-C may either neutralize inhaledLPS or may act as
a shuttle to allow the binding of LPS to distinct receptors
on alveolarmacrophages. These immunological findings
may explain why exogeneous SP-C showed a beneficial
effect in a porcine model of LPS-induced lung injury
[109].Respiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
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Pathogenesis of surfactant protein C associated lung disease
The current model of SP-C associated lung disease sug-
gests two mechanisms how aberrant forms of SP-C may
cause interstitial lung disease.
• Heterozygous mutations in the SP-C gene produce an
aberrant proSP-C protein. This aberrant protein interacts
with the regular intracellular pathway of SP-C biosynthe-
sis. Consequently, this leads to inhibition of functionally
active SP-C production and results in a SP-C deficiency in
the alveolus.
• When aberrant proSP-C is produced in large amounts, it
cannot be handled by the protein degradation pathway
and induces cellular injury and pulmonary inflammation
resulting in interstitial lung disease. Figure 1 depicts sev-
eral hypothesized pathways in the pathogenesis of SP-C
associated ILD according to Beers [78].
SP-C associated lung disease may be caused either by a
lack of mature SP-C, by the accumulation of aberrant,
toxic proSP-C or by both mechanisms. In humans with
SP-C mutations, additional factors, e.g. viral infections,
hypoxia or drugs, may trigger the accumulation of mis-
folded proprotein as the SP-C clearance pathway may
operate at its limiting capacity. Since SP-C is suggested to
be involved in thealveolar reuptake of surfactant particles
and plays a role in innate immunity, it remains unclear
which specific activity causes the lung diseasein patients
with SP-C mutations.
Pathways in the pathogenesis of surfactant protein-C associated interstitiallung disease (according to Beers 2004 [74]) Figure 1
Pathways in the pathogenesis of surfactant protein-C associated interstitiallung disease (according to Beers 2004 [74]). LPS: 
lipopolysaccharide; MØ: macrophage
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BRICHOS domain
Recently, a conserved domain of ~100 amino acids,
termed BRICHOS domain, has been identified in several
previously unrelated proteins. These proteins include the
BRI family of proteins (linked to familial British and Dan-
ish dementia), chondromodulin-I associated with
chondrosarcoma, CA11 protein associated with stomach
cancer and the distal region of proSP-C (F94-I197) associ-
ated with ILD. In most of these proteins, the BRICHOS
domain is localized in the propeptide region that is
removed during proteolytic processing [110]. Mutations
in the SP-C gene can be classified depending on the
involvement of the BRICHOS domain (Table 2, Addi-
tional file 1, and more detailed in [78]). In vitro trafficking
experiments showed that constructs of BRICHOS domain
mutations, e.g. hSP-C∆ exon4  [83] and hSP-CL188Q  [81],
form large toxic intracellular aggregates, termed aggre-
somes [82,93]. In contrast, mutations outside the BRI-
CHOS domain, as hSP-CE66K  and hSP-CI73T, led to
aberrant proSP-C accumulation in a constitutive endo-
somal pathway which may inhibit the cellular surfactant
recycling system [78,82,88]. Clinically, mutations in the
BRICHOS domain resulted in a more severe pulmonary
phenotype, mostly associated with death in the neonatal
period, while non-BRICHOS mutations led to a milder
clinical course.
Amyloid fibril formation
Amyloid fibril formation represents a potential mecha-
nism how misfolded higher-order structures of SP-C pro-
teins may cause epithelial cell damage. At least 20
incurable diseases are associated with amyloid fibrils
including Alzheimer's disease and spongiform encepha-
lopathy [111]. The metastable α -helical domain of SP-C
was found to transform under certain circumstances into
energetical favored β -sheet aggregates, which polymerize
to an amyloid-like fibril formation [112]. Such amyloid-
like fibrils were isolatedfrom the BAL fluids of a PAP
patient and in low amounts of three healthy controls
[113]. The pathophysiological relevance of these findings
remains unclear but suggest that conditions, which alter
the secondary structure of SP-C in terms of predisposing
to intracellular fibril formation, may have deleterious
effects on type II cells. These findings support the model
of a conformational lung disease due to a misfolded SP-
Cprotein [78]. Destabilizing point mutations may
enhance the transition of regular SP-C structure to patho-
logical forms [78].
ATP-Binding cassette (ABC) transporters
ABCA3
The ATP-binding cassette (ABC) transporters aremem-
brane proteins that utilize the energy of ATP hydrolysis to
translocate solutes across cellular membranes. Fourteen
ABC genes have been associated withdistinct genetic dis-
eases in humans including Tangier-disease and cystic
fibrosis [114,115]. ABCA3 is a 1704 amino acid protein-
whichis highly expressed in type II epithelial cells at the
limiting membraneof lamellar bodies. The structureand
localization of the ABCA3 transporter suggest a potential-
role in intracellular lipid homeostasis of lamellar bodies
[116]. Mutations in the ABCA3 gene are the most recently
described inborn error of surfactant metabolism [16].
Shulenin et al. identified mutations in the ABCA3 as a
cause of fatal RDS in newborn infants and theunderlying
cause of chronic ILD in one child living up to 6 years of
age. In 21 infantswith severe neonatal surfactant defi-
ciency in which SP-B and SP-C mutations had been
excluded, the coding regions of the ABCA3 genewere
sequenced. Furthermore, lung tissue from four patients
was analyzed. In 16 of the 21 patients, nonsense,
frameshift and splice sites mutations were found. These
patients included five consanguineous families. The con-
sanguinity and a family historyof neonatal respiratory dis-
tress suggest that the lung disease associatedwith
mutations in the ABCA3 gene were inherited in an auto-
somal-recessive manner. A mutation on one allele was
identified in two patients who showed a similarclinical
presentation as compared to the remaining patients.
Therefore the authors speculate that these children may
have a second mutation within introns or in regulatory
regions which was not detected by sequencing the coding
regions. The radiological findings and clinical symptoms
of infants with ABCA3 mutations were similar to new-
borns with SP-B deficiency. One infant with a missense
mutation on one allele was still alive at six years of age
showing lung histology of a ILD/DIP, suggesting that
some ABCA3 mutations are not fatal and may result in a
milder course of disease. Histological examination in
these patients showed type II cells hyperplasia and accu-
mulation of alveolar macrophageswith proteinaceous
materialand interstitial thickening, indicating DIP and
neonatal PAP. Electron microscopy revealed abnormally
small lamellar bodies indicating that the ABCA3 trans-
porter is critical for proper formation of the lamellar bod-
ies. A defectivetransport of lamellar-body associated lipid
components may result in abnormal processing and struc-
ture of surfactant. Furthermore, the mutant ABCA3 trans-
porter may transfer lipids which are deleteriousto the
function of alveolar surfactant. These findings suggest that
a high percentage of unclear casesof lethal neonatal lung
disease may be due to mutations in the ABCA3 gene and
affected families could benefit from genetic counseling.
Since there are no therapies known for the lung disease
due to ABCA3 mutations, the majority of affected new-
borns die from respiratory failure in the neonatal period.
Except for one patient, the phenotype of non-fatal lung
disease caused by ABCA3 mutations is unknown and
requires screening for ABCA3 mutations in neonates andRespiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
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children with severe ILD where no underlying cause can
be found [16].
ABCA1
A recent in vitro study showed that surfactant synthesis
and export are associated with a basolateral lipid efflux
pathway which is mediated by ABCA1, suggesting a role
for ABCA1 in the regulation of cellular content and com-
position of pulmonary surfactant [117]. Targeted disrup-
tion of the ABCA1 locus resulted in distinctive pulmonary
features [118]. Macroscopically, multiple pale foci were
found in the lungs which increased in severity withage,
affecting <10% of the parenchyma in 7 months-old mic-
eto 30% in 18 months-old mice. These lesionsconsisted of
foamy hypertrophic type II cells, alveolar macrophages
and cholesterol clefts. Furhermore, alveolar septae were
thickened by aggregates of lymphocytes and plasma cells.
In more severe lesions, pulmonary architecture collapsed
due to hypertrophic and hyperplastic type II pneumo-
cytes. Oil red staining showed lipid accumulation within
alveolar cells and electron microscopy identified these
cells as type II pneumocytes and intraalveolar macro-
phages. The possible role of ABCA1 in ILD is unknown
and there are no reports on ABCA1 mutations associated
with lung disease in humans.
Genes involved in lung morphogenesis, surfactant protein 
expression and lamellar body synthesis
Besides SP-B, SP-C and ABCA3, there is a number of genes
involved in lung morphogenesis, surfactant expression
and lamellar body function which may also play a role in
ILD in children.
Lung morphogenesis is a complex process mediated by
numerous transcription factors [11,119], growth factors
[120,121] and other signalling molecules that coordi-
natealveolar cell proliferation and differentiation. Factors
playing important rolesin lung morphogenesis include
thyroid transcription factor-1(TTF-1) [122-124], GATA-6
[125,126], Foxa2 [127], Hoxb5 [128], TGF-β  via SMADs
[129,130], CREB [131], Glucocorticoid Receptor [132],
HNF-3β  [133], N-myc [134] and members of the Gli fam-
ily [119]. Knock-out mice of these genes have provided
insight into the function during lung development
[119,135]. For example, Foxa2 expressionwas found to be
restricted to subsets of respiratory epithelial cells and was
co-expressed with TTF-1, CCSP, SP-A, SP-B, SP-C and SP-
D [127,136]. In a mouse model, deletion of Foxa2 in pul-
monary epithelialcells inhibited the differentiationof res-
piratory epithelial cells and resulted in neonatal
respiratoryfailure with hyaline membranes as typically
found in preterm infants with RDS.
TTF-1
TTF-1 is a member of the Nkx2.1 family which is involved
in thyroid and lung epithelial-specific gene expression
[124,137,138]. Co-transfection assays showed that TTF-1
activity is stimulatedby HNF-3β  and GATA-6 which are
co-expressed with TTF-1 in the developing lung [139].
While TTF-1 serves overall as an important regulator of
surfactant protein gene expression [140], a regulatory role
for HNF-3β  has been reported only for SP-B [141] and
CCSP [142] expression. Furthermore, TTF-1 and HNF-3β
were shown to functionally interact in the regulation of
the SP-B and CCSP promoter activity [122,143]. TTF-1
deficient pulmonaryepithelial cells failed to express
mature SP-B, SP-C and CCSP [124,144]. Deletion of TTF-
1 in mice caused thyroid and lungabnormalities with tra-
cheal-esophageal fistulaand dysgenesis of the peripheral
lung resulting in respiratoryfailure at birth [145,146]. In
humans, mutations in the TTF-1 gene were associated
with chorea, hypothyroidism and respiratory distress in
newborns [147-149]. Furterhmore TTF-1 gene variants
were found in older children with choreoathetosis,
hypothyroidism and respiratory distress [150].
Growth factors and cytokines
Various growth factors and cytokines have been described
to regulate surfactant protein gene expression in the fetal
lung [121]. Epidermal growth factor (EGF) was found to
increase SP-C gene expression [151], while TGF-β  and
TNF-α  inhibited surfactant protein expression. In mice
homozygous for a targeted deletion of the EGF receptor,
defects in surfactant function and in SP-A and SP-C
expression were observed [152]. The inhibitory effect of
TGF-β  on surfactant protein gene expression in the fetal
lung was found to be mediated at the transcriptional level
[26] through SMAD3 interactions with TTF-1 and HNF-3β
[153].
Lamellar body associated molecules
Lamellar bodies have an acidic interior (pH≈ 5.5) and con-
tain lysosomal enzymes (e.g. cathepsins C and H) and
lamellar body associated membrane proteins (LAMP; e.g.
LAMP1 [154], LAMP2 [155] and LAMP3 [156]). Recently,
the dendritic cell-lysosomal associated membrane protein
(DC-LAMP) was detected intracellularly and at the cell
surface of type II pneumocytes. Since type II cells constitu-
tively express MHC class II molecules, it is suggested that
they may act as antigen-presentingcells. Since DC-LAMP is
expressed on type II cells and on dendritic cells, a relation-
ship between DC-LAMP and MHC II function in type II
pneumocytes has been suggested [157,158]. Recently, a
study showed that the proteins t-SNARE, syntaxin 2 and
SNAP-23 were expressed in alveolar type II cells and were
associated with the plasma and lamellar body membrane.
SNAP23 was found to be required for the fusion of lamel-
lar bodies with the plasma membrane. An antisense oligo-Respiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
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nucleotide for syntaxin 2 inhibited surfactant secretion.
These results suggest that syntaxin 2 and SNAP-23 are
required for regulated surfactant exocytosis in type II cells
[159].
The characterization of molecules involvedin surfactant
protein gene expression, lung morphogenesis and lamel-
lar body synthesis expands the current model how a
network of genes may cause, trigger or promote lung dis-
ease. However, most of these genes causedlethal lung mal-
formations rather than chronic lung diseases and were
only studied in animal models [11]. Nevertheless, the
potential role of these genes in pediatric lung disease is
still unclear and requires further investigation. Insights on
how these molecules are involved in human lung physiol-
ogy may reveal new candidate genes for identifying muta-
tions associated with ILD in children.
Hermansky-Pudlak syndrome
In the autosomal-recessive disorder Hermansky-Pudlak-
Syndrome (HPS), most prevalent among Puerto Ricans,
the biogenesis of lysosomes and lysosome-related
organelles is affected. In humans, six different forms of
HPS have been described referring to the genes HPS 1 to
6. In patients with HPS, the molecular defect leads to
hypopigmentation, bleeding disorders and fibrotic lung
disease, mostly UIP. The incidence and severity of pulmo-
nary involvement in HPS patients varies widely but the
forms HPS1 and HPS4 were most likely associated with
ILD [160-162]. Lung tissue from HPS patients with ILD
exhibits giant lamellar bodies in type II epithelial cells,
patchy fibrosis and airspace enlargement [163].
Conclusion
Surfactant protein B
The lethal lung disease in SP-B deficient mice and humans
demonstrates the crucial role for SP-B in neonatal lung
function. The accumulation of aberrant proSP-C in SP-B
deficiency strongly suggests an important intracellular
role for SP-B in the processing of SP-C. The clinical pheno-
type of hereditary SP-B deficiency presents typically as
full-term neonates with severe respiratory distress syn-
drome refractory to standard therapies, includingventila-
tion and surfactant replacement. Lung transplantation is
regarded as the only effective treatment. Chest X-rays are
similar to those of premature infants with respiratory dis-
tress syndrome showing diffuse ground glass pattern.
Alveolar proteinosis is the predominant pathological phe-
notype. The SP-B 121ins2 mutation is suggested to
account for up to two-thirds of the mutant alleles identi-
fied in the SP-B gene. The overall incidence of hereditary
SP-B deficiency can be estimated from the allele frequency
of the 121ins2 mutation of 1 per 1000–3000 individuals.
Of great interest for clinical practice are some cases with
partial SP-B deficiency. These patients showed less severe
clinical phenotypes and prolonged survival into child-
hood with chronic lung disease and oxygen dependency
as compared to fully SP-B deficient patients. Thus, it is
likely that partial SP-B deficiency may be the underlying
cause in some children with unexplained chronic lung
disease.
Surfactant protein C
SP-C mutations were found to be associated with ILD in
neonates and children with sporadic or autosomal-domi-
nant inheritance. The majority of these mutations were
missenses or deletions leading to skipping of exon 4 or
substitution of highly conserved amino acids in the region
of the proSP-C molecule. In vitro studies support the
hypothesis that the identified SP-C mutations were caus-
ally related to the associated lung disease. The phenotype
covers a wide range of clinical features and age of onset.
Reported symptoms include respiratory distress with dys-
pnoea, tachypnea, cyanosis, asthmatic bronchitis and fail-
ure to thrive. The histological diagnosis was mostly NSIP,
in some cases combined with PAP. Adults with SP-C
mutations showed UIP or DIP while other subjects
remained asymptomatic. The phenotype of lung disease
associated with SP-C mutations may represent pleiotropic
manifestations of the same underlying pathogenesis.
Affected individuals may carry a genetic risk for interstitial
lung disease, which becomes apparent in dependence of
the genetic background, i.e. modifier genes and environ-
mental influences. These findings have essential implica-
tionsfor the diagnosis of ILD in children as genetic
diagnoses can be made and underlying etiologies of famil-
iar cases of ILD may be identified. In children with ILD,
where no underlying cause can be found, the patient's
DNA, BAL and lung tissue and the parents' DNA should
be conserved for genetical, biochemical and histological
analysis. Since the incidence and prevalence of ILD asso-
ciated with SP-C gene mutations are unknown it is neces-
sary to analyse larger subsets of clinically well defined
patient cohorts.
ABCA3
Mutations in the ATP-binding cassette transporter ABCA3
gene are the most recently described hereditary disorders
of surfactant metabolism. In 16 of 21 patients, who had
no mutations in the SP-B or SP-C gene, mutations in
ABCA3 were found inherited in an autosomal-recessive
manner. Clinical symptoms and radiological findings of
infants with ABCA3 mutations were similar to newborns
with SP-B deficiency. Histological diagnoses included
DIP, neonatal PAP and CPI. Interestingly, one infant with
a missense mutation on one allele was still alive at six
years of age showing lung histology of DIP, suggesting
that ABCA3 mutations may also result in a milder course
of disease. These findings indicate that a high percentage
of unclear casesof lethal neonatal lung disease may be dueRespiratory Research 2005, 6:32 http://respiratory-research.com/content/6/1/32
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to mutations in the ABCA3 gene and affected families
could benefit from genetic counseling. Except for one
patient, the phenotype of non-fatal lung disease caused by
ABCA3 mutations is unknown and requires screening for
ABCA3 mutations in neonates and children with severe
ILD where no underlying cause can be found.
Table 3 (Additional file 1) gives an overview of pediatric
ILD associated with surfactant protein deficiency or
ABCA3 mutations. In full-term neonates with unex-
plained, severe respiratory distress, refractory to therapeu-
tical efforts, genetic analysis of the SP-B and ABCA3
coding sequences are warranted. In children with progres-
sive interstitial lung disease, where no underlying cause
can be found, a genetic analysis of the SP-C gene may be
useful, especially in cases with a family history of unclear
lung disease.
Abbreviations
ABCA1 ATP-binding cassette transporter A1
ABCA3 ATP-binding cassette transporter A3
CPI chronic pneumonitis of infancy
DIP desquamative interstitial pneumonitis
GM-CSF granulocyte-macrophagecolony-stimulating
factor
ILD interstitial lung disease
LAMP lamellar body associated membrane protein
LPS lipopolysaccharide
NSIP non-specific interstitial pneumonitis
PAP pulmonary alveolar proteinosis
RDS respiratory distress syndrome
SNP single nucleotide polymorphism
SP surfactant protein
TTF-1 thyroid transcription factor-1
URD unexplained respiratory distress
UIP usual interstitial pneumonitis
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